Efficacy and safety of once-weekly Tirzepatide, a dual GIP/GLP-1 receptor agonist vs. placebo as monotherapy in people with type 2 diabetes (SURPASS-1)
With the increasing prevalence of diabetes, new treatment approaches are in need of time. Rosenstock J and colleagues conducted research under the title “Efficacy...